|
1
|
Soares KC and Jarnagin WR: The landmark
series: Hilar cholangiocarcinoma. Ann Surg Oncol. 28:4158–4170.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Banales JM, Marin JJG, Lamarca A,
Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen
JB, Braconi C, et al: Cholangiocarcinoma 2020: The next horizon in
mechanisms and management. Nat Rev Gastroenterol Hepatol.
17:557–588. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tan EK, Taner T, Heimbach JK, Gores GJ and
Rosen CB: Liver transplantation for peri-hilar cholangiocarcinoma.
J Gastrointest Surg. 24:2679–2685. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Villard C, Jorns C and Bergquist A:
Treatment of cholangiocarcinoma in patients with primary sclerosing
cholangitis: A comprehensive review. eGastroenterology.
2(e100045)2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kang MJ, Jang JY, Chang J, Shin YC, Lee D,
Kim HB and Kim SW: Actual long-term survival outcome of 403
consecutive patients with hilar cholangiocarcinoma. World J Surg.
40:2451–2459. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Heimbach JK, Gores GJ, Haddock MG, Alberts
SR, Nyberg SL, Ishitani MB and Rosen CB: Liver transplantation for
unresectable perihilar cholangiocarcinoma. Semin Liver Dis.
24:201–207. 2004.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rahbari NN, Garden OJ, Padbury R,
Brooke-Smith M, Crawford M, Adam R, Koch M, Makuuchi M, Dematteo
RP, Christophi C, et al: Posthepatectomy liver failure: A
definition and grading by the international study group of liver
surgery (ISGLS). Surgery. 149:713–724. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Balzan S, Belghiti J, Farges O, Ogata S,
Sauvanet A, Delefosse D and Durand F: The ‘50-50 criteria’ on
postoperative day 5: An accurate predictor of liver failure and
death after hepatectomy. Ann Surg. 242:824–829. 2005.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Semaan S, Connor AA, Saharia A, Kodali S,
Elaileh A, Patel K, Soliman N, Basra T, Victor DW III, Simon CJ, et
al: Transplantation for peri-hilar and intrahepatic
cholangiocarcinoma with mTOR immunosuppression. Transplant Proc.
57:255–263. 2025.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gilbert TM, Hackett J, Holt L, Bird N,
Quinn M, Gordon-Weeks A, Diaz-Nieto R, Fenwick SW, Malik HZ and
Jones RP: Long-term morbidity after surgery for perihilar
cholangiocarcinoma: A cohort study. Surg Oncol.
45(101875)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Nooijen LE, Banales JM, de Boer MT,
Braconi C, Folseraas T, Forner A, Holowko W, Hoogwater FJH, Klümpen
HJ, Groot Koerkamp B, et al: Impact of positive lymph nodes and
resection margin status on the overall survival of patients with
resected perihilar cholangiocarcinoma: The ENSCCA registry. Cancers
(Basel). 14(2389)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Safarpour AR, Askari H, Ejtehadi F,
Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A, Abazari MF, Tarkesh
F, Shamsaeefar A, Niknam R, et al: Cholangiocarcinoma and liver
transplantation: What we know so far? World J Gastrointest
Pathophysiol. 12:84–105. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Groot Koerkamp B, Wiggers JK, Allen PJ,
Besselink MG, Blumgart LH, Busch OR, Coelen RJ, D Angelica MI,
DeMatteo RP, Gouma DJ, et al: Recurrence rate and pattern of
perihilar cholangiocarcinoma after curative intent resection. J Am
Coll Surg. 221:1041–1049. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ota Y, Matsuyama R, Taniguchi K, Ueda M,
Takeda K, Tanaka K, Nakayama T and Endo I: Solitary rib recurrence
of hilar cholangiocarcinoma 10 years after resection: Report of a
case. Clin J Gastroenterol. 6:485–489. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Catanzaro E, Gringeri E, Burra P and
Gambato M: Primary sclerosing cholangitis-associated
cholangiocarcinoma: From pathogenesis to diagnostic and
surveillance strategies. Cancers (Basel). 15(4947)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW,
Chang HM, Bao L, Sun HC, Macarulla T, Xie F, et al: Zanidatamab for
HER2-amplified, unresectable, locally advanced or metastatic
biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm,
phase 2b study. Lancet Oncol. 24:772–782. 2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Vivaldi C, Fornaro L, Ugolini C, Niccoli
C, Musettini G, Pecora I, Cacciato Insilla A, Salani F, Pasquini G,
Catanese S, et al: HER2 overexpression as a poor prognostic
determinant in resected biliary tract cancer. Oncologist.
25:886–893. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hori Y, Yoh T, Seo S, Minamiguchi S, Haga
H and Taura K: Limited Impact of HER2 Expression on Survival
Outcomes in Patients with Intrahepatic Cholangiocarcinoma After
Surgical Resection. Oncologist. 26:e1893–e1894. 2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kim Y, Jee S, Kim H, Paik SS, Choi D, Yoo
SH and Shin SJ: EGFR, HER2, and MET gene amplification and protein
expression profiles in biliary tract cancer and their prognostic
significance. Oncologist. 29:e1051–e1060. 2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Oura K, Morishita A, Nakahara M, Tadokoro
T, Fujita K, Tani J, Masaki T and Kobara H: Chronic Liver Disease
Associated Cholangiocarcinoma: Genomic Insights and Precision
Therapeutic Strategies. Cancers (Basel). 17(3052)2025.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Goeppert B, Roessler S, Renner M, Singer
S, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfeld C,
et al: Mismatch repair deficiency is a rare but putative
therapeutically relevant finding in non-liver fluke associated
cholangiocarcinoma. Br J Cancer. 120:109–114. 2019.PubMed/NCBI View Article : Google Scholar
|
